Free Trial
NASDAQ:SELB

Selecta Biosciences (SELB) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.88
$1.26
52-Week Range
N/A
Volume
2.77 million shs
Average Volume
979,585 shs
Market Capitalization
$136.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.80

Selecta Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
∞ Upside
$2.80 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.33) to ($0.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.56 out of 5 stars

Medical Sector

404th out of 896 stocks

Biotechnology Industry

3rd out of 10 stocks

SELB stock logo

About Selecta Biosciences Stock (NASDAQ:SELB)

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

SELB Stock News Headlines

Jeff Bezos & 48 Members of Congress Are Buying ONE Sector…
Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…
Cartesian Therapeutics Inc (RNAC)
Pared-down Selecta merges with Maryland biotech
Selecta Biosciences Merges With Cartesian Therapeutics In All-stock Deal
Jeff Bezos & 48 Members of Congress Are Buying ONE Sector…
Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…
Selecta Biosciences Inc SELB
Analyst Ratings for Selecta Biosciences
Selecta Biosciences (SELB) Gets a Buy from H.C. Wainwright
Q2 2023 Selecta Biosciences Inc Earnings Call
See More Headlines
Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/17/2023
Today
6/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:SELB
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.80
High Stock Price Target
$5.00
Low Stock Price Target
$1.00
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$35.38 million
Pretax Margin
-73.23%

Debt

Sales & Book Value

Annual Sales
$110.78 million
Book Value
$0.61 per share

Miscellaneous

Free Float
106,780,000
Market Cap
$136.76 million
Optionable
Optionable
Beta
0.84
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Carsten Brunn Ph.D. (Age 52)
    CEO, President & Director
    Comp: $914.66k
  • Mr. Blaine T. Davis (Age 49)
    Chief Financial Officer
    Comp: $370.34k
  • Dr. Lloyd Johnston Ph.D. (Age 55)
    Chief Operating Officer
    Comp: $589.81k
  • Dr. Takashi Kei Kishimoto Ph.D. (Age 63)
    Chief Scientific Officer
    Comp: $599.81k
  • Dr. Peter G. Traber M.D. (Age 68)
    Chief Medical Officer
    Comp: $670.29k
  • Dr. Ulrich H. von Andrian-Werburg M.D.
    Ph.D., Co-Founder and Co-Chair of the Scientific Advisory Board
  • Mr. Matthew Bartholomae J.D.
    General Counsel & Secretary
  • Ms. Kristen Baldwin
    Chief People Officer
  • Ms. Ann K. Donohue CPA (Age 41)
    VP of Finance & Controller
    Comp: $286.97k

SELB Stock Analysis - Frequently Asked Questions

Should I buy or sell Selecta Biosciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SELB shares.
View SELB analyst ratings
or view top-rated stocks.

What is Selecta Biosciences' stock price target for 2024?

6 brokerages have issued twelve-month target prices for Selecta Biosciences' shares. Their SELB share price targets range from $1.00 to $5.00. On average, they anticipate the company's stock price to reach $2.80 in the next year.
View analysts price targets for SELB
or view top-rated stocks among Wall Street analysts.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) announced its quarterly earnings results on Thursday, August, 17th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.05. The firm had revenue of $5.25 million for the quarter, compared to the consensus estimate of $9.90 million. Selecta Biosciences had a negative trailing twelve-month return on equity of 44.13% and a negative net margin of 72.04%.

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

When did Selecta Biosciences IPO?

Selecta Biosciences (SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

This page (NASDAQ:SELB) was last updated on 6/23/2024 by MarketBeat.com Staff

From Our Partners